PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE
14. Dezember 2017 06:00 ET
|
Provectus Biopharmaceuticals Inc.
– Protection expands coverage for combinations of intralesional PV-10 with checkpoint inhibitors for multiple solid tumor cancers – KNOXVILLE, TN, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Provectus...